1. Home
  2. FRBA vs ANNX Comparison

FRBA vs ANNX Comparison

Compare FRBA & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bank

FRBA

First Bank

HOLD

Current Price

$16.76

Market Cap

377.6M

Sector

Finance

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.29

Market Cap

334.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRBA
ANNX
Founded
2007
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
377.6M
334.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FRBA
ANNX
Price
$16.76
$5.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$19.00
$16.50
AVG Volume (30 Days)
76.0K
3.0M
Earning Date
01-26-2026
11-10-2025
Dividend Yield
1.47%
N/A
EPS Growth
3.13
N/A
EPS
1.65
N/A
Revenue
$135,175,000.00
N/A
Revenue This Year
$15.53
N/A
Revenue Next Year
$5.97
N/A
P/E Ratio
$9.90
N/A
Revenue Growth
9.51
N/A
52 Week Low
$12.74
$1.29
52 Week High
$18.11
$5.73

Technical Indicators

Market Signals
Indicator
FRBA
ANNX
Relative Strength Index (RSI) 52.36 61.16
Support Level $16.11 $4.55
Resistance Level $16.84 $5.73
Average True Range (ATR) 0.49 0.35
MACD -0.11 -0.02
Stochastic Oscillator 32.04 67.09

Price Performance

Historical Comparison
FRBA
ANNX

About FRBA First Bank

First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of businesses. Its services are Business Banking; Personal banking; Digital Banking; and Lending.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: